Summary
The usefulness of bone turnover markers in Gaucher disease is still unclear and their utility in monitoring the effects of enzyme replacement therapy (ERT) on bone metabolism has not yet been investigated exhaustively. Skeletal involvement seems to improve slowly during ERT, but only a few studies evaluating bone mineral density (BMD) changes during a long follow-up period have been reported. The aim of this study was to assess the efficacy of ERT on bone involvement in a group of 12 type I Gaucher disease (GD I) patients by monitoring biochemical indices of bone resorption/formation and BMD measured by dual energy x-ray absorptiometry (DEXA). Serum (calcium, phosphorus, bone alkaline phosphatase isoenzyme, carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin, intact parathyroid hormone) and urinary (calcium, phosphorus, hydroxyproline and free deoxypyridinoline) markers of bone metabolism and lumbar BMD were measured at baseline, after 6 and 12 months, and then every year for a mean ERT follow-up period of 4.5 years (range 4.4–6 years). Twelve healthy adult subjects matched for age and sex were tested as negative controls. A significant decrease of PICP was detected in the patient group at baseline (mean value 100.52 ng/ml vs 142.45 ng/ml, p = 0.017), while ICTP was remarkably higher: mean value 3.93 ng/ml vs 2.72 ng/ml, p = 0.004 (two-sided Student’s t-test). No changes in bone formation indices were observed during the follow-up period, while urinary calcium excretion increased significantly from 0.065 to 0.191 mg/mg creatinine (p = 0.0014) (repeated measures ANOVA). A significant BMD improvement was also detected after an average ERT period of 4.5 years: Z-score increased from −0.81 to −0.56 (p = 0.005) (two-sided Student’s t-test). These data evidenced the ineffectiveness of the biochemical markers used in monitoring ERT efficacy in GD I skeletal involvement, whereas DEXA was demonstrated to be a reliable method with which to follow up BMD improvement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen MJ, Myer BJ, Khoker AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher disease: increased release of interleukin-6 and interleukin-10. Q J Med 90: 19–25.
Barak V, Acker M, Nisman B, et al (1999) Cytokines and Gaucher’s disease. Eur Cytokine Netw 10: 205–210.
Bembi B, Zanatta M, Carozzi M, et al (1994) Enzyme replacement treatment in type 1 and type 3 Gaucher disease. Lancet 344: 1679–1682.
Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.
Ciana G, Cuttini M, Bembi B (1997) Short term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement. N Engl J Med 337: 712.
Ciana G, Martini C, Leopaldi A, et al (2003) Bone marker alterations in patients with type I Gaucher disease. Calcif Tissue Int 72: 185–189.
Delmas PD, Eastell R, Garnero P, Seible MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors in the International Osteoporosis Foundation. Osteoporos Int 11(Supplement 6): S2–S17.
Drugan C, Jebelenau G, Grigorescu-Sido P, Caillaud C, Cracium AM (2002) Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28: 13–20.
Elstein D, Itzchaki M, Mankin HJ (1997) Skeletal involvement in Gaucher’s disease. Bailliere’s Clin Haematol 10: 793–816.
Fiore CE, Barone R, Pennisi P, Pavone V, Riccobene S (2002) Bone ultrasonometry, bone density and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 20: 34–38.
Herman G, Goldblatt J, Levy RN, Goldsmith SJ, Desnick RJ, Grabowski GA (1986) Gaucher’s disease type I: assessment of bone involvement by CT and scintigraphy. AJR Am J Roengtenol 147: 943–948.
Johnston CC Jr, Slemenda CW, Melton LJ 3rd (1991) Clinical use of bone densitometry. N Engl J Med 324: 1105–1109.
Pastores GM, Wallenstein S, Desnick RJ, Luckey MM (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11: 1801–1807.
Poll LW, Maas M, Terk MR, et al (2002) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(supplement 1): A25–36.
Rose JS, Grabowski GA, Barnettt SH, Desnick RJ (1982) Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease. Am J Roengtenol 139: 1202–1204.
Rosenthal DI, Mayo-Smith W, Goodsit MM, Doppelt SH, Mankin HJ (1989) Bone and bone marrow changes in Gaucher disease: evaluation with quantitative CT. Radiology 170: 143–146.
Rosenthal DI, Barton NW, McCusick KA, et al (1992) Quantitative imaging of Gaucher disease. Radiology 185: 841–845.
Rosenthal DI, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–637.
Schiffmann R, Mankin H, Dambrosia JM (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28: 288–296.
Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA (1985) Skeletal complications of Gaucher disease. Medicine 64: 310–322.
Watts NB (1999) Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 1359–1368.
Wenstrap RJ, Bailey L, Grabowsky GA, et al (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme replacement therapy. Blood 104(5): 1253–1257.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciana, G., Addobbati, R., Tamaro, G. et al. Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28, 723–732 (2005). https://doi.org/10.1007/s10545-005-0032-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-005-0032-y